Evaluation of a Novel Arg-Gly-Asp-conjugated α-melanocyte Stimulating Hormone Hybrid Peptide for Potential Melanoma Therapy

Overview

Journal Bioconjug Chem

Publisher American Chemical Society

Specialty Biochemistry

Date 2009 Jun 26

PMID 19552406

Citations 24

Authors

Jianquan Yang

Haixun Guo

Fabio Gallazzi

Marianne Berwick

R Steven Padilla

Yubin Miao

Affiliations

Soon will be listed here.

Abstract

Unlabelled: The purpose of this study was to determine whether Arg-Gly-Asp (RGD)-conjugated α-melanocyte stimulating hormone (α-MSH) hybrid peptide could be employed to target melanocortin-1 (MC1) receptor for potential melanoma therapy.

Methods: The RGD motif {cyclic(Arg-Gly-Asp-DTyr-Asp)} was coupled to [Cys(3,4,10), DPhe(7), Arg(11)]α-MSH(3-13) {(Arg(11))CCMSH} to generate RGD-Lys-(Arg(11))CCMSH hybrid peptide. The MC1 receptor binding affinity of RGD-Lys-(Arg(11))CCMSH was determined in B16/F1 melanoma cells. The internalization and efflux, melanoma targeting and pharmacokinetic properties and single photon emission computed tomography/CT (SPECT/CT) imaging of (99m)Tc-RGD-Lys-(Arg(11))CCMSH were determined in B16/F1 melanoma cells and melanoma-bearing C57 mice. Clonogenic cytotoxic effect of RGD-Lys-(Arg(11))CCMSH was examined in B16/F1 melanoma cells.

Results: RGD-Lys-(Arg(11))CCMSH displayed 2.1 nM MC1 receptor binding affinity. (99m)Tc-RGD-Lys-(Arg(11))CCMSH showed rapid internalization and extended retention in B16/F1 cells. The cellular uptake of (99m)Tc-RGD-Lys-(Arg(11))CCMSH was MC1 receptor-mediated. (99m)Tc-RGD-Lys-(Arg(11))CCMSH exhibited high tumor uptake (14.83 ± 2.94% ID/g 2 h postinjection) and prolonged tumor retention (7.59 ± 2.04% ID/g 24 h postinjection) in B16/F1 melanoma-bearing mice. Nontarget organ uptakes were generally low except for the kidneys. Whole-body clearance of (99m)Tc-RGD-Lys-(Arg(11))CCMSH was rapid, with approximately 62% of the injected radioactivity cleared through the urinary system by 2 h postinjection. Flank melanoma tumors were clearly imaged by small animal SPECT/CT using (99m)Tc-RGD-Lys-(Arg(11))CCMSH as an imaging probe 2 h postinjection. Single treatment (3 h incubation) with 100 nM of RGD-Lys-(Arg(11))CCMSH significantly (p < 0.05) decreased the clonogenic survival of B16/F1 cells by 65% compared to the untreated control cells.

Conclusion: Favorable melanoma targeting property of (99m)Tc-RGD-Lys-(Arg(11))CCMSH and remarkable cytotoxic effect of RGD-Lys-(Arg(11))CCMSH in B16/F1 cells warranted the further evaluation of (188)Re-labeled α-MSH hybrid peptides as novel therapeutic peptides for melanoma treatment once the strategies of amino acid coinjection or structural modification of peptide sequence substantially reduce the renal uptake.

Citing Articles

Elevating theranostics: The emergence and promise of radiopharmaceutical cell-targeting heterodimers in human cancers.

Chambers C, Chitwood B, Smith C, Miao Y iRadiology. 2024; 2(2):128-155.

PMID: 38708130 PMC: 11067702. DOI: 10.1002/ird3.62.

Decreased expression of predicts a poor prognosis in melanoma using bioinformatics analysis.

Ni Q, Li X, Huang H, Ge Z Front Oncol. 2023; 13:1015358.

PMID: 37035142 PMC: 10079878. DOI: 10.3389/fonc.2023.1015358.

Development and Evaluation of a Peptide Heterodimeric Tracer Targeting CXCR4 and Integrin αβ for Pancreatic Cancer Imaging.

Jiang Y, Long Y, Ji H, Qiao P, Liu Q, Xia X Pharmaceutics. 2022; 14(9).

PMID: 36145541 PMC: 9503769. DOI: 10.3390/pharmaceutics14091791.

Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFA-Modified Peptidic Radioligands Targeting Both Integrin αβ and the MC1 Receptor-Suitable for the Specific Visualization of Melanomas?.

Cheng X, Hubner R, von Kiedrowski V, Fricker G, Schirrmacher R, Wangler C Pharmaceuticals (Basel). 2021; 14(6).

PMID: 34200477 PMC: 8228600. DOI: 10.3390/ph14060547.

Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy.

Judmann B, Braun D, Wangler B, Schirrmacher R, Fricker G, Wangler C Pharmaceuticals (Basel). 2020; 13(8).

PMID: 32751666 PMC: 7465997. DOI: 10.3390/ph13080173.

References

Anderson C, Buzaid A, Legha S . Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park). 1995; 9(11):1149-58; discussion 1163-4, 1167-8. View

Capello A, Krenning E, Bernard B, Breeman W, van Hagen M, de Jong M . Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med. 2004; 45(10):1716-20. View

Schraa A, Kok R, Moorlag H, Bos E, Proost J, Meijer D . Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study. Int J Cancer. 2002; 102(5):469-75. DOI: 10.1002/ijc.10727. View

Siegrist W, Solca F, Stutz S, GIUFFRE L, Carrel S, Girard J . Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 1989; 49(22):6352-8. View

Chen J, Cheng Z, Hoffman T, Jurisson S, Quinn T . Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res. 2000; 60(20):5649-58. View

Capello A, Krenning E, Bernard B, Breeman W, Erion J, de Jong M . Anticancer activity of targeted proapoptotic peptides. J Nucl Med. 2006; 47(1):122-9. View

Balch C, Soong S, Gershenwald J, Thompson J, Reintgen D, Cascinelli N . Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19(16):3622-34. DOI: 10.1200/JCO.2001.19.16.3622. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

Burke P, DeNardo S, Miers L, Lamborn K, Matzku S, DeNardo G . Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002; 62(15):4263-72. View

10.

Miao Y, Gallazzi F, Guo H, Quinn T . 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjug Chem. 2008; 19(2):539-47. PMC: 3617549. DOI: 10.1021/bc700317w. View

11.

Hofland L, Capello A, Krenning E, de Jong M, van Hagen M . Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides. J Nucl Med. 2005; 46 Suppl 1:191S-8S. View

12.

Froidevaux S, Calame-Christe M, Tanner H, Sumanovski L, Eberle A . A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med. 2002; 43(12):1699-706. View

13.

Heppeler A, Froidevaux S, Eberle A, Maecke H . Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem. 2000; 7(9):971-94. DOI: 10.2174/0929867003374516. View

14.

Miao Y, Owen N, Whitener D, Gallazzi F, Hoffman T, Quinn T . In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer. 2002; 101(5):480-7. DOI: 10.1002/ijc.10640. View

15.

Brooks P, Montgomery A, Rosenfeld M, Reisfeld R, Hu T, Klier G . Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994; 79(7):1157-64. DOI: 10.1016/0092-8674(94)90007-8. View

16.

Miao Y, Benwell K, Quinn T . 99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med. 2007; 48(1):73-80. View

17.

Fung S, Hruby V . Design of cyclic and other templates for potent and selective peptide alpha-MSH analogues. Curr Opin Chem Biol. 2005; 9(4):352-8. PMC: 1820743. DOI: 10.1016/j.cbpa.2005.06.010. View

18.

Buckley C, Pilling D, Henriquez N, Parsonage G, Threlfall K, Scheel-Toellner D . RGD peptides induce apoptosis by direct caspase-3 activation. Nature. 1999; 397(6719):534-9. DOI: 10.1038/17409. View

19.

Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall J . In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer. 2000; 87(5):716-23. View

20.

Miao Y, Figueroa S, Fisher D, Moore H, Testa R, Hoffman T . 203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med. 2008; 49(5):823-9. PMC: 3610567. DOI: 10.2967/jnumed.107.048553. View